APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents (OHAs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Hypoglycemic Agents (OHAs) Market Analysis and Forecast 2026-2032

20 December 2025190 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents (OHAs) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents (OHAs) Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents (OHAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents (OHAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents (OHAs) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents (OHAs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral Hypoglycemic Agents (OHAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Hypoglycemic Agents (OHAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Hypoglycemic Agents (OHAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Hypoglycemic Agents (OHAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral Hypoglycemic Agents (OHAs) include Bristol-Myers Squibb, Double-Crane Pharmaceutical, Novonordisk, Sanofi-Aventis, Servier, Bayer, Wanbang Biopharmaceuticals, GlaxoSmithKline and Guangzhou Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Hypoglycemic Agents (OHAs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Hypoglycemic Agents (OHAs), also provides the sales of main regions and countries. Of the upcoming market potential for Oral Hypoglycemic Agents (OHAs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Hypoglycemic Agents (OHAs) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Hypoglycemic Agents (OHAs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral Hypoglycemic Agents (OHAs) sales, projected growth trends, production technology, application and end-user industry.

Oral Hypoglycemic Agents (OHAs) Segment by Company

Bristol-Myers Squibb

Double-Crane Pharmaceutical

Novonordisk

Sanofi-Aventis

Servier

Bayer

Wanbang Biopharmaceuticals

GlaxoSmithKline

Guangzhou Pharmaceutical

Huadong Medicine

Pfizer

Oral Hypoglycemic Agents (OHAs) Segment by Type

Alpha-Glucosidase Inhibitors

Metformin

Sulfonylureas

Thiazolidinediones

Oral Hypoglycemic Agents (OHAs) Segment by Application

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Oral Hypoglycemic Agents (OHAs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents (OHAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents (OHAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents (OHAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral Hypoglycemic Agents (OHAs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Hypoglycemic Agents (OHAs) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Alpha-Glucosidase Inhibitors Major Manufacturers Table 3. Metformin Major Manufacturers Table 4. Sulfonylureas Major Manufacturers Table 5. Thiazolidinediones Major Manufacturers Table 6. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Type 2 Diabetes Mellitus Major Manufacturers Table 8. Type 1 Diabetes Mellitus Major Manufacturers Table 9. Oral Hypoglycemic Agents (OHAs) Industry Trends Table 10. Oral Hypoglycemic Agents (OHAs) Industry Drivers Table 11. Oral Hypoglycemic Agents (OHAs) Industry Opportunities and Challenges Table 12. Oral Hypoglycemic Agents (OHAs) Industry Restraints Table 13. Global Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2021-2026) Table 17. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2027-2032) Table 18. Global Oral Hypoglycemic Agents (OHAs) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2021-2026) & (K Units) Table 20. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2027-2032) & (K Units) Table 21. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2021-2026) Table 22. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2027-2032) Table 23. Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2021-2026) Table 27. Global Oral Hypoglycemic Agents (OHAs) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Oral Hypoglycemic Agents (OHAs) Manufacturers, Product Type & Application Table 31. Global Oral Hypoglycemic Agents (OHAs) Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Oral Hypoglycemic Agents (OHAs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2026) Table 38. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2027-2032) Table 39. Global Oral Hypoglycemic Agents (OHAs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 41. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 42. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2026) Table 43. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2027-2032) Table 44. Global Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2026) & (US$/Unit) Table 45. Global Oral Hypoglycemic Agents (OHAs) Price by Type (2027-2032) & (US$/Unit) Table 46. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2026) Table 50. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2027-2032) Table 51. Global Oral Hypoglycemic Agents (OHAs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 53. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 54. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2026) Table 55. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2027-2032) Table 56. Global Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2026) & (US$/Unit) Table 57. Global Oral Hypoglycemic Agents (OHAs) Price by Application (2027-2032) & (US$/Unit) Table 58. Bristol-Myers Squibb Company Information Table 59. Bristol-Myers Squibb Business Overview Table 60. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 62. Bristol-Myers Squibb Recent Development Table 63. Double-Crane Pharmaceutical Company Information Table 64. Double-Crane Pharmaceutical Business Overview Table 65. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 67. Double-Crane Pharmaceutical Recent Development Table 68. Novonordisk Company Information Table 69. Novonordisk Business Overview Table 70. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 72. Novonordisk Recent Development Table 73. Sanofi-Aventis Company Information Table 74. Sanofi-Aventis Business Overview Table 75. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 77. Sanofi-Aventis Recent Development Table 78. Servier Company Information Table 79. Servier Business Overview Table 80. Servier Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 82. Servier Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 87. Bayer Recent Development Table 88. Wanbang Biopharmaceuticals Company Information Table 89. Wanbang Biopharmaceuticals Business Overview Table 90. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 92. Wanbang Biopharmaceuticals Recent Development Table 93. GlaxoSmithKline Company Information Table 94. GlaxoSmithKline Business Overview Table 95. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 97. GlaxoSmithKline Recent Development Table 98. Guangzhou Pharmaceutical Company Information Table 99. Guangzhou Pharmaceutical Business Overview Table 100. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 102. Guangzhou Pharmaceutical Recent Development Table 103. Huadong Medicine Company Information Table 104. Huadong Medicine Business Overview Table 105. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 107. Huadong Medicine Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 112. Pfizer Recent Development Table 113. North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 116. North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 117. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 118. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 119. North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 122. North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 123. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 124. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 125. North America Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 127. North America Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 128. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 129. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 130. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 131. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 132. North America Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 133. United States Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 134. Canada Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 135. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 136. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 137. Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 138. Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 139. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 140. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 141. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 144. Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 145. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 146. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 147. Europe Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 149. Europe Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 150. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 151. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 152. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 153. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 154. Europe Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 155. Germany Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 156. France Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 157. U.K. Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 158. Italy Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 159. Netherlands Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 160. China Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 161. China Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 162. China Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 163. China Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 164. China Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 165. China Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 166. China Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 167. China Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 168. China Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 169. China Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 170. China Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 171. China Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 172. Asia Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 175. Asia Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 176. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 177. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 178. Asia Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 179. Asia Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 180. Asia Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 181. Asia Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 182. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 183. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Asia Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. Asia Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 189. Asia Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 190. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 191. Asia Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Japan Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 193. South Korea Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 194. India Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 195. Australia Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 196. China Taiwan Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 198. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 201. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 202. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 203. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 204. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (US$ Million) Table 205. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (US$ Million) Table 206. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 207. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 208. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 209. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 210. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 214. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 215. SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 216. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 217. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 218. Brazil Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 219. Argentina Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 220. Chile Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 221. Colombia Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 222. Peru Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 224. Israel Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 225. UAE Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 226. Turkey Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 227. Iran Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 228. Egypt Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Oral Hypoglycemic Agents (OHAs) Distributors List Table 232. Oral Hypoglycemic Agents (OHAs) Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents (OHAs) Image Figure 2. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents (OHAs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Alpha-Glucosidase Inhibitors Image Figure 5. Metformin Image Figure 6. Sulfonylureas Image Figure 7. Thiazolidinediones Image Figure 8. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Oral Hypoglycemic Agents (OHAs) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Type 2 Diabetes Mellitus Image Figure 11. Type 1 Diabetes Mellitus Image Figure 12. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Figure 14. Global Oral Hypoglycemic Agents (OHAs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2021-2032) Figure 17. Global Oral Hypoglycemic Agents (OHAs) Sales (2021-2032) & (K Units) Figure 18. Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Oral Hypoglycemic Agents (OHAs) Sales YoY (2021-2032) & (K Units) Figure 21. Europe Oral Hypoglycemic Agents (OHAs) Sales YoY (2021-2032) & (K Units) Figure 22. China Oral Hypoglycemic Agents (OHAs) Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Oral Hypoglycemic Agents (OHAs) Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales YoY (2021-2032) & (K Units) Figure 25. Global Oral Hypoglycemic Agents (OHAs) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Oral Hypoglycemic Agents (OHAs) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2032) Figure 31. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2032) Figure 34. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2032) Figure 37. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2032) Figure 40. North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2021-2032) Figure 41. North America Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2021-2032) Figure 42. North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2021-2032) Figure 43. North America Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2021-2032) Figure 44. North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2021-2032) Figure 45. North America Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2021-2032) Figure 46. Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2021-2032) Figure 47. Europe Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2021-2032) Figure 48. Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2021-2032) Figure 49. Europe Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2021-2032) Figure 50. Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2021-2032) Figure 51. Europe Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2021-2032) Figure 52. China Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2021-2032) Figure 53. China Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2021-2032) Figure 54. China Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2021-2032) Figure 55. China Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2021-2032) Figure 56. Asia Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2021-2032) Figure 57. Asia Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2021-2032) Figure 58. Asia Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2021-2032) Figure 59. Asia Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2021-2032) Figure 60. Asia Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2021-2032) Figure 61. Asia Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2021-2032) Figure 62. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2021-2032) Figure 63. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2021-2032) Figure 64. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2021-2032) Figure 65. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2021-2032) Figure 66. SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2021-2032) Figure 67. SAMEA Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2021-2032) Figure 68. Oral Hypoglycemic Agents (OHAs) Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Oral Hypoglycemic Agents (OHAs) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-Glucosidase Inhibitors
  • Metformin
  • Sulfonylureas
  • Thiazolidinediones
Applications
  • Type 2 Diabetes Mellitus
  • Type 1 Diabetes Mellitus
Companies covered
  • Bristol-Myers Squibb
  • Double-Crane Pharmaceutical
  • Novonordisk
  • Sanofi-Aventis
  • Servier
  • Bayer
  • Wanbang Biopharmaceuticals
  • GlaxoSmithKline
  • Guangzhou Pharmaceutical
  • Huadong Medicine
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Hypoglycemic Agents (OHAs) Market by Type
  3. 1.2.1 Global Oral Hypoglycemic Agents (OHAs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Alpha-Glucosidase Inhibitors
  5. 1.2.3 Metformin
  6. 1.2.4 Sulfonylureas
  7. 1.2.5 Thiazolidinediones
  8. 1.3 Oral Hypoglycemic Agents (OHAs) Market by Application
  9. 1.3.1 Global Oral Hypoglycemic Agents (OHAs) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Type 2 Diabetes Mellitus
  11. 1.3.3 Type 1 Diabetes Mellitus
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Oral Hypoglycemic Agents (OHAs) Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents (OHAs) Industry Trends
  2. 2.2 Oral Hypoglycemic Agents (OHAs) Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents (OHAs) Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents (OHAs) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region
  3. 3.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral Hypoglycemic Agents (OHAs) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral Hypoglycemic Agents (OHAs) Sales by Region
  9. 3.4.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2021-2026)
  11. 3.4.3 Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2027-2032)
  12. 3.4.4 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers
  2. 4.1.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral Hypoglycemic Agents (OHAs) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers
  6. 4.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral Hypoglycemic Agents (OHAs) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral Hypoglycemic Agents (OHAs) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral Hypoglycemic Agents (OHAs) Manufacturers, Product Type & Application
  13. 4.7 Global Oral Hypoglycemic Agents (OHAs) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral Hypoglycemic Agents (OHAs) Market CR5 and HHI
  16. 4.8.2 2025 Oral Hypoglycemic Agents (OHAs) Tier 1, Tier 2, and Tier 3
5 Oral Hypoglycemic Agents (OHAs) Market by Type
  1. 5.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type
  2. 5.1.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type
  6. 5.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type
6 Oral Hypoglycemic Agents (OHAs) Market by Application
  1. 6.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application
  2. 6.1.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application
  6. 6.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Double-Crane Pharmaceutical
  8. 7.2.1 Double-Crane Pharmaceutical Company Information
  9. 7.2.2 Double-Crane Pharmaceutical Business Overview
  10. 7.2.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
  12. 7.2.5 Double-Crane Pharmaceutical Recent Developments
  13. 7.3 Novonordisk
  14. 7.3.1 Novonordisk Company Information
  15. 7.3.2 Novonordisk Business Overview
  16. 7.3.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio
  18. 7.3.5 Novonordisk Recent Developments
  19. 7.4 Sanofi-Aventis
  20. 7.4.1 Sanofi-Aventis Company Information
  21. 7.4.2 Sanofi-Aventis Business Overview
  22. 7.4.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio
  24. 7.4.5 Sanofi-Aventis Recent Developments
  25. 7.5 Servier
  26. 7.5.1 Servier Company Information
  27. 7.5.2 Servier Business Overview
  28. 7.5.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio
  30. 7.5.5 Servier Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 Wanbang Biopharmaceuticals
  38. 7.7.1 Wanbang Biopharmaceuticals Company Information
  39. 7.7.2 Wanbang Biopharmaceuticals Business Overview
  40. 7.7.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio
  42. 7.7.5 Wanbang Biopharmaceuticals Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 Guangzhou Pharmaceutical
  50. 7.9.1 Guangzhou Pharmaceutical Company Information
  51. 7.9.2 Guangzhou Pharmaceutical Business Overview
  52. 7.9.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
  54. 7.9.5 Guangzhou Pharmaceutical Recent Developments
  55. 7.10 Huadong Medicine
  56. 7.10.1 Huadong Medicine Company Information
  57. 7.10.2 Huadong Medicine Business Overview
  58. 7.10.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio
  60. 7.10.5 Huadong Medicine Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
8 North America
  1. 8.1 North America Oral Hypoglycemic Agents (OHAs) Market Size by Type
  2. 8.1.1 North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  4. 8.1.3 North America Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
  5. 8.2 North America Oral Hypoglycemic Agents (OHAs) Market Size by Application
  6. 8.2.1 North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  8. 8.2.3 North America Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
  9. 8.3 North America Oral Hypoglycemic Agents (OHAs) Market Size by Country
  10. 8.3.1 North America Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral Hypoglycemic Agents (OHAs) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Type
  2. 9.1.1 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
  5. 9.2 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Application
  6. 9.2.1 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
  9. 9.3 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Country
  10. 9.3.1 Europe Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral Hypoglycemic Agents (OHAs) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Oral Hypoglycemic Agents (OHAs) Market Size by Type
  2. 10.1.1 China Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  3. 10.1.2 China Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  4. 10.1.3 China Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
  5. 10.2 China Oral Hypoglycemic Agents (OHAs) Market Size by Application
  6. 10.2.1 China Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  7. 10.2.2 China Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  8. 10.2.3 China Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Hypoglycemic Agents (OHAs) Market Size by Type
  2. 11.1.1 Asia Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
  5. 11.2 Asia Oral Hypoglycemic Agents (OHAs) Market Size by Application
  6. 11.2.1 Asia Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
  9. 11.3 Asia Oral Hypoglycemic Agents (OHAs) Market Size by Country
  10. 11.3.1 Asia Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral Hypoglycemic Agents (OHAs) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Hypoglycemic Agents (OHAs) Market Size by Type
  2. 12.1.1 SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
  5. 12.2 SAMEA Oral Hypoglycemic Agents (OHAs) Market Size by Application
  6. 12.2.1 SAMEA Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
  9. 12.3 SAMEA Oral Hypoglycemic Agents (OHAs) Market Size by Country
  10. 12.3.1 SAMEA Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral Hypoglycemic Agents (OHAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral Hypoglycemic Agents (OHAs) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral Hypoglycemic Agents (OHAs) Value Chain Analysis
  2. 13.1.1 Oral Hypoglycemic Agents (OHAs) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral Hypoglycemic Agents (OHAs) Production Mode & Process
  6. 13.2 Oral Hypoglycemic Agents (OHAs) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral Hypoglycemic Agents (OHAs) Distributors
  9. 13.2.3 Oral Hypoglycemic Agents (OHAs) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst